Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indication Matters: Study Shows Trial Characteristics Of Approved Drugs Vary Widely Across Diseases

Executive Summary

FDA data requirements supporting novel drug approvals vary widely, depending on therapeutic area, with cancer drugs given greatest leniency, suggesting products may need a clinical trial “quality grade,” according to an analysis published in the Journal of the American Medical Association. Another study shows cancer treatments are most likely to get approved on the first try.


Related Content

Systematizing Patient Views Unlikely, FDA’s Temple Says
R&D Productivity Still Lags: Study Shows Success Rates May Have Been Overestimated
Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
FDA Puts “Safety First” For Post-Market Issues
IoM Drug Safety Report Recommends Sweeping Changes At CDER





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts